These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30370041)

  • 21. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients.
    Nazzaro G; Calzari P; Passoni E; Vaienti S; Moltrasio C; Barbareschi M; Muratori S; Veraldi S; Marzano AV
    Dermatol Ther; 2021 Jan; 34(1):e14706. PubMed ID: 33368976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of Life of Patients With Hidradenitis Suppurativa in Jeddah, Saudi Arabia.
    Alamri AM; Alzahrani AA; Aldakhil AM; Alharbi HE; Yahya FA
    Cureus; 2021 Dec; 13(12):e20234. PubMed ID: 34909350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52-week analysis of a postmarketing surveillance study in Japan.
    Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
    J Dermatol; 2023 Aug; 50(8):1034-1044. PubMed ID: 37264993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Takekuni N; Takahashi K; Matsuyama T; Okubo Y; Zhao Y; Kitamura S; Takei K; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2021 Jan; 48(1):3-13. PubMed ID: 33029861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study.
    Martora F; Marasca C; Cacciapuoti S; Fariello F; Potestio L; Battista T; Scalvenzi M; Megna M
    Clin Cosmet Investig Dermatol; 2024; 17():159-166. PubMed ID: 38283798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
    Amano M; Grant A; Kerdel FA
    Int J Dermatol; 2010 Aug; 49(8):950-5. PubMed ID: 21128923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LOSS OF EFFICACY OF ADALIMUMAB IN HIDRADENITIS SUPPURATIVA: FOCUS ON ALTERNATIVES.
    Tchernev G
    Georgian Med News; 2023; (340-341):297-300. PubMed ID: 37805915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab for the treatment of hidradenitis suppurativa/acne inversa.
    Zouboulis CC
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1015-26. PubMed ID: 27531618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.
    Zouboulis CC; Tzellos T; Kyrgidis A; Jemec GBE; Bechara FG; Giamarellos-Bourboulis EJ; Ingram JR; Kanni T; Karagiannidis I; Martorell A; Matusiak Ł; Pinter A; Prens EP; Presser D; Schneider-Burrus S; von Stebut E; Szepietowski JC; van der Zee HH; Wilden SM; Sabat R;
    Br J Dermatol; 2017 Nov; 177(5):1401-1409. PubMed ID: 28636793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
    Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Collantes-Rodríguez C; Rodríguez C; Linares-Barrios M
    Cytokine; 2018 Mar; 103():20-24. PubMed ID: 29289722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.
    Sotiriou E; Goussi C; Lallas A; Chovarda E; Apalla Z; Lazaridou E; Ioannides D
    J Drugs Dermatol; 2012 May; 11(5 Suppl):s15-20. PubMed ID: 22644772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis.
    Montero-Vilchez T; Diaz-Calvillo P; Rodriguez-Pozo JA; Cuenca-Barrales C; Martinez-Lopez A; Arias-Santiago S; Molina-Leyva A
    Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34206415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa.
    Jepsen R; Edwards C; Flora A; Kozera E; Frew JW
    J Am Acad Dermatol; 2023 Oct; 89(4):694-702. PubMed ID: 37307994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real life data on the biopsychosocial effects of Adalimumab in the management of hidradenitis suppurativa: A multicenter cross sectional analysis and consideration of a multisystem monitoring approach to follow up.
    Muralidharan V; Pathmarajah P; Peterknecht E; Qazi E; Barlow R; Muralidharan V; Abdullah A; McDonald B; Bewley A
    Dermatol Ther; 2021 Jan; 34(1):e14643. PubMed ID: 33296539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Staphylococcus aureus Carriage in Hidradenitis Suppurativa: Impact on Response to Adalimumab.
    Stergianou D; Tzanetakou V; Argyropoulou M; Kanni T; Bagos PG; Giamarellos-Bourboulis EJ
    Dermatology; 2021; 237(3):372-377. PubMed ID: 33401280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of Life in Hidradenitis Suppurativa: An Update.
    Chernyshov PV; Finlay AY; Tomas-Aragones L; Poot F; Sampogna F; Marron SE; Zemskov SV; Abeni D; Tzellos T; Szepietowski JC; Zouboulis CC
    Int J Environ Res Public Health; 2021 Jun; 18(11):. PubMed ID: 34204126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [CME Dermatology 23: Hidradenitis suppurativa].
    Dahmen RA; Lautenschlager S
    Praxis (Bern 1994); 2021; 110(7):363-372. PubMed ID: 34019444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
    Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
    Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.
    Daoud M; Suppa M; Benhadou F; Daxhelet M; Njimi H; White J; Jemec G; Del Marmol V
    Front Med (Lausanne); 2023; 10():1145152. PubMed ID: 37138732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.